I-Mab (IMAB) Competitors

I-Mab (NASDAQ:IMAB) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Is IMAB or MAZE more profitable?

Maze Therapeutics' return on equity of 0.00% beat I-Mab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	-19.81%	-18.63%
Maze Therapeutics	N/A	N/A	N/A

Does the media prefer IMAB or MAZE?

In the previous week, I-Mab had 2 more articles in the media than Maze Therapeutics. MarketBeat recorded 5 mentions for I-Mab and 3 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 0.83 beat I-Mab's score of 0.31 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maze Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation and earnings, IMAB or MAZE?

Maze Therapeutics has higher revenue and earnings than I-Mab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	45.55	-$22.23M	N/A	N/A
Maze Therapeutics	$167.50M	4.48	$52.23M	N/A	N/A

Do insiders & institutionals have more ownership in IMAB or MAZE?

38.4% of I-Mab shares are held by institutional investors. 22.1% of I-Mab shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts prefer IMAB or MAZE?

I-Mab currently has a consensus target price of $6.00, suggesting a potential upside of 176.50%. Maze Therapeutics has a consensus target price of $23.50, suggesting a potential upside of 37.27%. Given I-Mab's higher probable upside, analysts plainly believe I-Mab is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Maze Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.33

Summary

Maze Therapeutics beats I-Mab on 7 of the 12 factors compared between the two stocks.